Galmed Pharmaceuticals Ltd

Eocene Ltd. is a biopharmaceutical company focused on developing therapeutics for liver diseases and related indications. Its lead candidate, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate in a Phase III study as an oral treatment for non-alcoholic steatohepatitis (NASH) in overweight or obese patients with prediabetes or type II diabetes mellitus. Aramchol is also being evaluated in the Phase IIa ARRIVE Study in HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company is additionally developing Amilo-5MER, a synthetic peptide of five amino acids (methionine, threonine, alanine, aspartic acid, and valine), and MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma Co., Ltd. for commercialization of Aramchol in the Republic of Korea, and collaboration agreements with OnKai for its AI platform and with Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. The company was founded in 2000 and is headquartered in Ramat Gan, Israel.